Brief: Gossamer Bio Announces GB004 Topline Results From Phase 2 Shift-UC Study In Ulcerative Colitis

Gossamer Bio

25/04/2022 12:30

April 25 (Reuters) - Gossamer Bio Inc  GOSS.O :
    * GOSSAMER BIO ANNOUNCES GB004 TOPLINE RESULTS FROM PHASE 2 SHIFT-UC STUDY
IN
ULCERATIVE COLITIS AND PROVIDES CORPORATE UPDATE
    * GOSSAMER BIO INC - TARGET ENROLLMENT REACHED IN PHASE 2 TORREY STUDY OF
SERALUTINIB IN PAH; TOPLINE RESULTS EXPECTED IN 4Q22
    * GOSSAMER BIO INC - GB004 PHASE 2 SHIFT-UC STUDY TO BE TERMINATED FOR LACK
OF
TREATMENT BENEFIT
    * GOSSAMER BIO INC - STUDY DID NOT MEET PRIMARY OR SECONDARY ENDPOINTS AT
WEEK 12
    * GOSSAMER BIO INC - S OF MARCH 31, 2022, GOSSAMER ESTIMATES THAT ITS CASH,
CASH
EQUIVALENTS AND MARKETABLE SECURITIES WERE APPROXIMATELY $272 MILLION
    * GOSSAMER BIO INC - AS OF MARCH 31, 2022, GOSSAMER ESTIMATES THAT ITS CASH,
CASH
EQUIVALENTS AND MARKETABLE SECURITIES WERE APPROXIMATELY $272 MILLION
    * GOSSAMER BIO INC - NEITHER STATISTICALLY SIGNIFICANT NOR CLINICALLY
MEANINGFUL
DIFFERENCES WERE OBSERVED FOR PRIMARY ENDPOINT AT WEEK 12
    * GOSSAMER BIO INC - SAFETY AND TOLERABILITY PROFILE OF GB004 OBSERVED IN
TRIAL
WAS GENERALLY CONSISTENT WITH PRIOR CLINICAL TRIALS
    * GOSSAMER BIO INC - ADVERSE EVENTS WERE GENERALLY MILD IN SEVERITY

Source text for Eikon:  ID:nBw3Drc9Fa 
Further company coverage:  GOSS.O 

 ((Reuters.Briefs@thomsonreuters.com;))